Blueprint Medicines Corporation, based in Massachusetts, is a precision therapy company that develops medicines for genomically defined blood disorders and cancers worldwide. The company is working on several medications, including AYVAKIT, BLU-263, and Fisogatinib for the treatment of different types of cancer. Blueprint Medicines Corporation has a collaboration and licensing agreement with various other healthcare companies.